FMRP Expression Levels in Mouse Central Nervous System Neurons Determine Behavioral Phenotype

Area of Science:

• Neuroscience
• Genetics
• Molecular Biology

Background:

• Fragile X Syndrome (FXS) is a genetic disorder characterized by cognitive impairment and autistic behaviors due to reduced or absent Fragile X mental retardation protein (FMRP).
• Viral vector-based gene therapy shows promise for FXS, but precise control over therapeutic protein levels is challenging.

Purpose of the Study:

• To investigate the effects of varying neuronal Fragile X mental retardation protein (FMRP) expression levels on the phenotype of Fmr1 knockout mice.
• To determine the optimal range of FMRP expression for rescuing FXS-associated abnormalities.

Main Methods:

• Adeno-associated viral vectors encoding FMRP were administered intra-cerebroventricularly to Fmr1 knockout and wild-type mice.
• FMRP transgene expression levels were quantified across brain regions.
• Synaptic protein levels (PSD-95), transcriptional modulator levels (MeCP2), and behavioral phenotypes (motor activity, anxiety, acoustic startle) were assessed.

Main Results:

• FMRP expression between 35-115% of wild-type levels in Fmr1 knockout mice rescued synaptic deficits and behavioral abnormalities.
• Moderate FMRP overexpression (up to twofold) in wild-type mice had minimal impact.
• Excessive FMRP overexpression (2.5-6-fold) in knockout mice induced hyperactivity and suppressed startle responses.

Conclusions:

• A specific range of FMRP expression is critical for therapeutic efficacy in Fragile X Syndrome.
• These findings inform the development of gene therapy strategies for FXS and other neurodevelopmental disorders, emphasizing the importance of dose-dependent expression levels.